Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB)

About the company

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

17

CEO

Jed Andrew Latkin

Exchange

NYSE American

Website

http://www.navidea.com

$1.00M

Total Revenue

17

Employees

$68.85M

Market Capitalization

-6.23

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$1M

Operating Margin (in %)

Total operating margin

$-9M

Net Margin (in %)

Total net margin

$-1M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Johnson & Johnson JNJ 381124.48 82729.00 6.12 22.21 20.75
Merck & Co., Inc. MRK 196889.19 48081.00 7.39 19.43 21.10
Pfizer Inc. PFE 190835.04 50660.00 2.89 12.08 31.17
Eli Lilly & Co. LLY 149964.48 23087.00 50.89 26.43 23.97
AbbVie, Inc. ABBV 143695.72 34057.00 -23.00 17.14 24.65
Bristol Myers Squibb Co. BMY 107221.81 31006.00 2.60 91.16 3.08
Repligen Corp. RGEN 6432.63 286.00 6.17 280.29 8.11
Reata Pharmaceuticals, Inc. RETA 4786.40 20.00 22.67 -15.39 -150.30
Nektar Therapeutics NKTR 4229.28 137.00 3.30 -9.21 -335.62
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 3855.28 1.00 35.64 -5.90 None
Allakos, Inc. ALLK 3213.86 None 6.98 -34.36 None
Karuna Therapeutics, Inc. KRTX 2505.88 None 6.54 -61.78 None
OPKO Health, Inc. OPK 2448.18 891.00 1.74 -8.37 -32.92
ADC Therapeutics SA ADCT 2343.60 2.00 27.64 -20.09 None
IGM Biosciences, Inc. IGMS 2191.70 None 9.66 -40.40 None
Turning Point Therapeutics, Inc. TPTX 2173.68 None 6.54 -18.19 None
Apellis Pharmaceuticals, Inc. APLS 2141.70 None 9.46 -5.13 None
Ra Pharmaceuticals, Inc. RARX 2111.78 3.00 8.68 -20.78 -585.71
Principia Biopharma, Inc. PRNB 1792.84 30.00 6.38 -25.51 -242.01
Springworks Therapeutics, Inc. SWTX 1651.20 None 5.36 -26.48 None
Y-mAbs Therapeutics, Inc. YMAB 1477.04 None 9.05 -16.03 None
Zymeworks, Inc. ZYME 1393.98 26.00 2.89 -8.22 -629.37
Tricida, Inc. TCDA 1300.46 None 6.69 -6.16 None
Akcea Therapeutics, Inc. AKCA 1261.97 341.00 2.59 -44.86 -8.59
Kiniksa Pharmaceuticals Ltd. KNSA 1223.75 None 6.34 -10.11 None
Odonate Therapeutics, Inc. ODT 1122.30 None 9.19 -9.97 None
Akero Therapeutics, Inc. AKRO 1092.43 None 9.12 -21.53 None
Arcutis Biotherapeutics, Inc. ARQT 1076.33 None 4.59 -17.21 None
Phibro Animal Health Corp. PAHC 1029.10 818.00 5.20 27.89 4.49
Athenex, Inc. ATNX 971.88 123.00 5.96 -9.03 -87.86
Constellation Pharmaceuticals, Inc. CNST 944.96 None 4.45 -10.18 None
Gossamer Bio, Inc. GOSS 798.49 None 3.24 -4.02 None
G1 Therapeutics, Inc. GTHX 774.63 1.00 3.35 -5.91 None
Quanterix Corp. QTRX 736.56 60.00 6.50 -16.84 -71.52
Phathom Pharmaceuticals, Inc. PHAT 731.00 None 4.06 -2.69 None
Krystal Biotech, Inc. KRYS 695.98 None 4.06 -33.56 None
Oric Pharmaceuticals, Inc. ORIC 691.88 None -7.51 -22.88 None
Applied Therapeutics, Inc. APLT 670.34 14.00 4.33 -13.60 -19.41
Provention Bio, Inc. PRVB 669.94 None 10.60 -15.13 None
Provention Bio, Inc. PRVB 651.88 None 10.31 -14.72 None
Amneal Pharmaceuticals, Inc. AMRX 637.05 1679.00 4.39 -2.92 -11.85
Aprea Therapeutics, Inc. APRE 617.82 None 5.47 -18.27 None
Arcturus Therapeutics Holdings, Inc. ARCT 609.57 19.00 56.49 -21.91 -151.34
Keros Therapeutics, Inc. KROS 601.74 8.00 -27.18 -28.33 -285.35
Oyster Point Pharma, Inc. OYST 534.45 None 5.37 -9.29 None
Mirum Pharmaceuticals, Inc. MIRM 491.75 None 3.20 -7.26 None
Osmotica Pharmaceuticals Plc OSMT 473.58 232.00 3.59 -1.72 -115.44
SIGA Technologies, Inc. SIGA 467.40 19.00 5.23 -23.75 -94.00
89bio, Inc. ETNB 451.08 None 5.56 -6.99 None
Fulcrum Therapeutics, Inc. FULC 445.97 1.00 7.52 -6.46 None
Biospecifics Technologies Corp. BSTC 442.47 40.00 3.59 18.93 61.80
Satsuma Pharmaceuticals, Inc. STSA 437.75 None 4.31 -12.03 None
Imara, Inc. IMRA 424.15 None 4.10 -12.05 None
DURECT Corp. DRRX 390.60 28.00 30.00 -16.15 -82.94
Relmada Therapeutics, Inc. RLMD 380.97 0.00 5.68 -31.83 -877.66
TCR2 Therapeutics, Inc. TCRR 368.88 None 2.52 -36.60 None
Crinetics Pharmaceuticals, Inc. CRNX 366.96 1.00 4.63 -6.29 -447.78
Kala Pharmaceuticals, Inc. KALA 365.76 6.00 4.00 -3.98 None
Ocular Therapeutix, Inc. OCUL 356.16 6.00 -43.65 -3.88 None
Ovid Therapeutics, Inc. OVID 336.15 None 7.95 -5.15 None
Aeglea Biotherapeutics, Inc. AGLE 292.05 4.00 9.22 -3.64 -523.27
Gritstone Oncology, Inc. GRTS 291.24 4.00 2.61 -2.79 None
Urovant Sciences Ltd. UROV 281.70 None -4.99 -1.95 None
HOOKIPA Pharma, Inc. HOOK 268.32 13.00 2.43 -5.93 -333.02
IDEAYA Biosciences, Inc. IDYA 266.80 None 4.05 -6.12 None
Spero Therapeutics, Inc. SPRO 247.38 12.00 3.26 -3.04 -656.72
AMAG Pharmaceuticals, Inc. AMAG 246.84 321.00 0.94 -0.67 -115.05
Verrica Pharmaceuticals, Inc. VRCA 238.50 None 4.36 -7.82 None
KalVista Pharmaceuticals, Inc. KALV 221.58 12.00 2.45 -6.84 -263.38
Lannett Co., Inc. LCI 218.12 542.00 0.75 -7.17 -5.77
Sutro Biopharma, Inc. STRO 207.46 41.00 3.94 -3.40 -148.06
Kaleido Biosciences, Inc. KLDO 202.80 None 7.19 -2.77 None
Veru, Inc. VERU 198.90 39.00 6.65 -20.40 -25.53
Galera Therapeutics, Inc. GRTX 179.50 None 3.36 -2.73 None
LogicBio Therapeutics, Inc. LOGC 177.79 1.00 5.37 -4.18 None
Protara Therapeutics, Inc. TARA 164.52 None 2.47 -10.67 None
Liquidia Technologies, Inc. LQDA 163.68 8.00 12.83 -3.32 -602.17
Avenue Therapeutics, Inc. ATXI 156.16 532.00 28.71 -10.73 26.69
Lyra Therapeutics, Inc. LYRA 150.84 1.00 -1.28 -9.04 -491.16
Cyclerion Therapeutics, Inc. CYCN 145.26 6.00 1.83 -1.40 None
scPharmaceuticals, Inc. SCPH 144.97 119.00 3.70 -4.62 -27.05
Tyme Technologies, Inc. TYME 140.30 None 8.13 -6.42 None
PhaseBio Pharmaceuticals, Inc. PHAS 137.17 2.00 2.54 -2.87 None
Evelo Biosciences, Inc. EVLO 134.40 None 4.94 -1.53 None
Harrow Health, Inc. HROW 130.26 51.00 8.35 -5.27 -47.54
Corvus Pharmaceuticals, Inc. CRVS 127.60 None 2.05 -2.70 None
Mustang Bio, Inc. MBIO 126.80 None 2.96 -2.58 None
Immunic, Inc. IMUX 122.70 None 3.61 -55.77 None
TFF Pharmaceuticals, Inc. TFFP 122.36 None 4.74 -3.16 None
Aquestive Therapeutics, Inc. AQST 120.12 49.00 -6.92 -1.71 -139.64
Ayala Pharmaceuticals, Inc. AYLA 120.00 3.00 -2.82 -5.81 -679.19
NeuBase Therapeutics, Inc. NBSE 116.06 None 48.76 -2.60 None
Trevi Therapeutics, Inc. TRVI 104.76 None 2.22 -3.57 None
Evolus, Inc. EOLS 96.00 45.00 1.72 -0.95 -217.51
Milestone Pharmaceuticals, Inc. MIST 92.25 None 0.91 -1.48 None
Eton Pharmaceuticals, Inc. ETON 90.90 1.00 9.90 -4.55 None
EyePoint Pharmaceuticals, Inc. EYPT 81.75 26.00 5.77 -1.67 -196.30
Xeris Pharmaceuticals, Inc. XERS 72.24 4.00 3.58 -0.56 None
Clearside Biomedical, Inc. CLSD 71.34 6.00 9.16 -4.05 -293.61
Checkpoint Therapeutics, Inc. CKPT 70.80 2.00 6.10 -3.05 -949.53
Navidea Biopharmaceuticals, Inc. NAVB 68.85 1.00 -50.63 -6.23 -65.13
Baudax Bio, Inc. BXRX 63.54 None -1.73 -0.91 None
Genprex, Inc. GNPX 59.09 None 5.02 -4.32 None
BiomX, Inc. PHGE 58.74 None 1.55 -1.37 None
Aridis Pharmaceuticals, Inc. ARDS 58.50 1.00 -24.07 -2.00 -851.00
Assertio Therapeutics, Inc. ASRT 58.32 192.00 1.01 -0.36 -83.99
Aerpio Pharmaceuticals, Inc. ARPO 51.66 20.00 1.56 -2.74 -51.58
Menlo Therapeutics, Inc. MNLO 48.43 2.00 4.07 -0.52 -483.51
Edesa Biotech, Inc. EDSA 43.29 0.00 6.17 -0.46 -395.23
Eyenovia, Inc. EYEN 42.56 None 4.29 -2.08 None
Annovis Bio, Inc. ANVS 42.28 None 3.87 -33.56 None
Moleculin Biotech, Inc. MBRX 39.38 None 3.42 -4.28 None
Akari Therapeutics Plc AKTX 36.18 None -33.50 -2.01 None
Citius Pharmaceuticals, Inc. CTXR 36.18 None 2.68 -2.09 None
Acer Therapeutics, Inc. ACER 35.00 3.00 2.55 -1.34 -274.69
AgeX Therapeutics, Inc. AGE 34.88 2.00 -45.90 -2.87 -658.11
Mannatech, Inc. MTEX 34.80 156.00 1.47 7.84 3.45
Adamis Pharmaceuticals Corp. ADMP 33.64 22.00 1.29 -1.14 -140.33
Allena Pharmaceuticals, Inc. ALNA 33.35 None 4.39 -0.77 None
Aileron Therapeutics, Inc. ALRN 29.96 None 4.12 -1.13 None
CNS Pharmaceuticals, Inc. CNSP 29.92 None 5.19 -5.50 None
Oncternal Therapeutics, Inc. ONCT 28.99 3.00 3.72 -1.15 -225.89
Millendo Therapeutics, Inc. MLND 25.95 0.00 0.61 -0.55 None
Hoth Therapeutics, Inc. HOTH 25.80 None 7.17 -2.87 None
Spring Bank Pharmaceuticals, Inc. SBPH 23.52 0.00 0.89 -0.90 None
Akorn, Inc. AKRX 22.68 721.00 -1.20 -0.06 -55.64
ProPhase Labs, Inc. PRPH 18.96 9.00 1.72 -6.32 -31.15
Daré Bioscience, Inc. DARE 18.91 1.00 8.29 -1.13 None
Novan, Inc. NOVN 14.82 5.00 -3.41 -0.47 -602.34
Adial Pharmaceuticals, Inc. ADIL 14.80 None 3.61 -1.95 None
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
PDS Biotechnology Corp. PDSB 14.14 None 1.57 -0.55 None
Titan Pharmaceuticals, Inc. TTNP 11.60 4.00 4.83 -0.64 -437.91
Novus Therapeutics, Inc. NVUS 7.74 None 0.66 -0.37 None
Brickell Biotech, Inc. BBI 4.65 5.00 1.52 -0.06 -432.19
BioStar Pharmaceuticals, Inc. BSPM 0.21 0.00 0.01 0.10 294.01

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Navidea Biopharmaceuticals Inc.

11d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Cut to “Sell” at Zacks Investment Research

8d ago, source: modernreaders.com

Zacks Investment Research lowered shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) from a hold rating to a sell ...

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

28d ago, source: GlobeNewswire

June 15, 2020 08:00 ET | Source: Navidea Biopharmaceuticals, Inc. DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB ...

BRIEF-Navidea Biopharma Announces Full Enrollment In Ongoing Phase 2B Trial Of Tc99m Tilmanocept

27d ago, source: Reuters

PHASE 2B TRIAL TO CONTINUE IN PARALLEL UNTIL COMPLETION * NAVIDEA BIOPHARMACEUTICALS INC - NAV3-31 PHASE 2B STUDY IS ON TRACK FOR LAST PATIENT TO BE SCREENED, AND EVALUATED BY END OF 2020 Source ...

Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock?

26d ago, source: YAHOO!

Investors in Navidea Biopharmaceuticals, Inc. NAVB need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, 2020 $2.00 Call had some of the ...

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

27d ago, source: MarketWatch

The MarketWatch News Department was not involved in the creation of this content. Jun 15, 2020 (NewMediaWire via COMTEX) -- Dublin, OH - (NewMediaWire (https://www.newmediawire.com)) - June 15 ...

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

27d ago, source: Benzinga.com

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.